OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans

Summary by AI BETAClose X

OKYO Pharma has filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2026, reporting a strengthened cash position of approximately $20.6 million as of March 31, 2026, bolstered by a February 2026 capital raise of approximately $22 million. This robust financial standing fully funds the completion of the NEPTUNE Phase 3 pivotal trial for urcosimod, a potential registrational study for neuropathic corneal pain, which is planned to initiate in the second half of 2026 with approximately 111 patients.

Disclaimer*

UK 100

Latest directors dealings